Search research articles
Contact Us
Filters
Showing results (191-200 of 203) with videos related to
Page
of 21
Sort By:
Plos One
|
May 9, 2017
Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052
Philip J Palumbo, Ethan A Wilson, Estelle Piwowar-Manning, et al.
JMIR Research Protocols
|
June 18, 2025
Improving HIV Prevention Among Heterosexual Men Seeking Sexually Transmitted Infection Services in Malawi: Protocol for a Type I Effectiveness-Implementation Hybrid Randomized Controlled Trial of Systems Navigator-Delivered Integrated Prevention Package (HPTN 112-NJIRA Study)
Sarah E Rutstein, Laura Limarzi-Klyn, Jane S Chen, et al.
Open Forum Infectious Diseases
|
November 3, 2025
Sustained HIV Suppression With Co-formulated Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir in a Person With Transmitted Dolutegravir Resistance and Pretreatment Resistance to Lamivudine: a Case Report From HPTN 083
Hannah P Moore, Jessica M Fogel, Mark A Marzinke, et al.
AIDS Research and Human Retroviruses
|
October 28, 2024
HIV DNA Levels in Persons Who Acquired HIV in the Setting of Long-Acting Cabotegravir for HIV Prevention: Analysis of Cases from HPTN 083 and 084
Jessica M Fogel, Deborah Persaud, Estelle Piwowar-Manning, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 27, 2026
Prospective HIV RNA screening with long-acting cabotegravir pre-exposure prophylaxis in HPTN 083
Raphael J Landovitz, Jessica M Fogel, Fei Gao, et al.
The Journal of Infectious Diseases
|
August 3, 2013
Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052)
Jessica M Fogel, Lei Wang, Teresa L Parsons, et al.
HIV Clinical Trials
|
April 8, 2017
Virologic outcomes in early antiretroviral treatment: HPTN 052
Susan H Eshleman, Ethan A Wilson, Xinyi C Zhang, et al.
The Journal of Infectious Diseases
|
March 19, 2021
Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
Mark A Marzinke, Beatriz Grinsztejn, Jessica M Fogel, et al.
Antimicrobial Agents and Chemotherapy
|
March 30, 2023
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
Mark A Marzinke, Jessica M Fogel, Zhe Wang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 10, 2016
Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial
Jessica M Fogel, Sarah E Hudelson, San-San Ou, et al.
Page
of 21
Search research articles
Search
Showing results (191-200 of 203) with videos related to
Sort By:
Page
of 21
Plos One
|
May 9, 2017
Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052
Philip J Palumbo, Ethan A Wilson, Estelle Piwowar-Manning, et al.
JMIR Research Protocols
|
June 18, 2025
Improving HIV Prevention Among Heterosexual Men Seeking Sexually Transmitted Infection Services in Malawi: Protocol for a Type I Effectiveness-Implementation Hybrid Randomized Controlled Trial of Systems Navigator-Delivered Integrated Prevention Package (HPTN 112-NJIRA Study)
Sarah E Rutstein, Laura Limarzi-Klyn, Jane S Chen, et al.
Open Forum Infectious Diseases
|
November 3, 2025
Sustained HIV Suppression With Co-formulated Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir in a Person With Transmitted Dolutegravir Resistance and Pretreatment Resistance to Lamivudine: a Case Report From HPTN 083
Hannah P Moore, Jessica M Fogel, Mark A Marzinke, et al.
AIDS Research and Human Retroviruses
|
October 28, 2024
HIV DNA Levels in Persons Who Acquired HIV in the Setting of Long-Acting Cabotegravir for HIV Prevention: Analysis of Cases from HPTN 083 and 084
Jessica M Fogel, Deborah Persaud, Estelle Piwowar-Manning, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 27, 2026
Prospective HIV RNA screening with long-acting cabotegravir pre-exposure prophylaxis in HPTN 083
Raphael J Landovitz, Jessica M Fogel, Fei Gao, et al.
The Journal of Infectious Diseases
|
August 3, 2013
Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052)
Jessica M Fogel, Lei Wang, Teresa L Parsons, et al.
HIV Clinical Trials
|
April 8, 2017
Virologic outcomes in early antiretroviral treatment: HPTN 052
Susan H Eshleman, Ethan A Wilson, Xinyi C Zhang, et al.
The Journal of Infectious Diseases
|
March 19, 2021
Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
Mark A Marzinke, Beatriz Grinsztejn, Jessica M Fogel, et al.
Antimicrobial Agents and Chemotherapy
|
March 30, 2023
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
Mark A Marzinke, Jessica M Fogel, Zhe Wang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 10, 2016
Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial
Jessica M Fogel, Sarah E Hudelson, San-San Ou, et al.
Page
of 21